Manuscripts in peer reviewed international journals 2022 – 2012 PubMed registered
Search PubMed: Kalland KH or ORCID ID https://orcid.org/0000-0003-4486-2334:
Thomsen LCV, Honoré A, Reisæter LAR, Almås B, Børretzen A, Helle SI, Førde K, Kristoffersen EK, Kaada SH, Melve GK, Haslerud TM, Biermann M, Bigalke I, Kvalheim G, Azeem W, Olsen JR, Gabriel B, Knappskog S, Halvorsen OJ, Akslen LA, Bahn D, Pantel K, Riethdorf S, Ragde H, Gjertsen BT, Øyan AM, Kalland KH, Beisland C. Autologous dendritic cell-based cryoimmunotherapy in a prospective, non-randomised phase I trial of metastatic castration-resistant prostate cancer (2023); Cancer Immunol. Immunother. doi: 10.1007/s00262-023-03421-7. PMID: 36939854
Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, Kalland KH. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. (2023) doi: 10.3389/fimmu.2022.1058963. eCollection 2022. PMID: 36713392
Hua Y, Yuan X, Shen YH, Wang J, Azeem W, Yang S, Gade A, Lellahi SM, Øyan AM, Ke X, Zhang WD, Kalland KH. Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain (2022). Front Pharmacol. 13:836724. doi: 10.3389/fphar.2022.836724. eCollection 2022. PMID: 35712699
Azeem W, Olsen JR, Hellem MR, Hua Y, Marvyin K, Ke X, Øyan AM, Kalland KH. Proteasome-Mediated Regulation of GATA2 Expression and Androgen Receptor Transcription in Benign Prostate Epithelial Cells (2022). Biomedicines 10(2):473. doi: 10.3390/biomedicines10020473.PMID: 35203681
Azeem W, Bakke RM, Gabriel B, Appel S, Øyan AM, Kalland KH. Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells (2021). Biomedicines 9(8):949 doi: 10.3390/biomedicines9080949
Nordgård O, Brendsdal Forthun R, Lapin M, Grønberg BH, Kalland KH, Kopperud RK, Thomsen LCV, Tjensvoll K, Gilje B, Gjertsen BT, Hovland R. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System (2021). Cancers (Basel) 13(8):1861. doi: 10.3390/cancers13081861.PMID: 33924696
Azeem W, Bakke RM, Appel S, Øyan AM, Kalland KH. Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells (2020). Front. Immunol. 11:438. https://doi.org/10.3389/fimmu.2020.00438
Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB. PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma (2019). Clin Cancer Res. 25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. PMID: 30442683
Kusonmano K, Halle MK, Wik E, Hoivik EA, Krakstad C, Mauland KK, Tangen IL, Berg A, Werner HMJ, Trovik J, Øyan AM, Kalland KH, Jonassen I, Salvesen HB, Petersen K. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer (2018). PLoS One 13(11):e0206665. doi: 10.1371/journal.pone.0206665. eCollection 2018.PMID: 30383835
Håvik AL, Bruland O, Aarhus M, Kalland KH, Stokowy T, Lund-Johansen M, Knappskog PM.Screening for viral nucleic acids in vestibular schwannoma (2018). J Neurovirol. 24(6):730-737. doi: 10.1007/s13365-018-0669-6. Epub 2018 Aug 30.PMID: 30168016
Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X (2018). Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology 14(1):94-101. PMID:29083417
Wang B, Tian T, Kalland KH, Ke X, Qu Y. Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy (2018). Trends Pharmacol Sci. 39(7):648-658. Review. PMID:29678298
Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions (2018). Br J Cancer 118:378-387. PMID:29169184
Hua Y, Azeem W, Shen Y, Zhang S, Olsen JR, Øyan AM, Ke X, Zhang W, Kalland KH. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain (2018). Pharmacol Res Perspect. 6(6):e00437. PMID:30410767.
Kusonmano K, Halle MK, Wik E, Hoivik EA, Krakstad C, Mauland KK, Tangen IL, Berg A, Werner HMJ, Trovik J, Øyan AM, Kalland KH, Jonassen I, Salvesen HB, Petersen K. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer (2018). PLoS One. 13(11):e0206665. PMID:30383835
Azeem W, Hellem MR, Olsen JR, Hua Y, Marvyin K, Qu Y, Lin B, Ke X, Øyan AM, Kalland KH. An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells (2017). PLoS One 12(6):e0177861. doi: 10.1371/journal.pone.0177861. eCollection. PMID:28570625
Qu Y, Kalland KH, Ke X. Small molecule induces Wnt asymmetry in cancer (2017). Cell Cycle 17;16:141-142. PMID: 27687486
Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Øyan AM, Bjørge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM.Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients (2017). Oncotarget. 8(63):106989-107001. doi: 10.18632/oncotarget.22203. eCollection PMID: 29291005
Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer (2017). Sci Rep. 31;7(1):10240. doi: 10.1038/s41598-017-10717-z. PMID: 28860563
Leiss L, Mutlu E, Øyan A, Yan T, Tsinkalovsky O, Sleire L, Petersen K, Rahman MA, Johannessen M, Mitra SS, Jacobsen HK, Talasila KM, Miletic H, Jonassen I, Li X, Brons NH, Kalland KH, Wang J, Enger PØ. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts (2017). BMC Cancer 108. doi: 10.1186/s12885-017-3109-8. PMID:28173797
Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival (2017). Oncotarget 8(6):9696-9707. doi: 10.18632/oncotarget.14201. PMID:28039471
Qu Y, Gharbi N, Yuan X, Olsen JR, Blicher P, Dalhus B, Brokstad KA, Lin B, Øyan AM, Zhang W, Kalland KH, Ke X. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer (2016). Proc Natl Acad Sci U S A. 113:9339-44. PMID: 27482107
Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Øyan AM, Kalland K. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes (2016). BMC Cancer. 16:377.
Litlekalsoy J, Rostad K, Kalland KH, Hostmark JG, Laerum OD. Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes (2016). BMC Cancer 16:549.
Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, Werner HM, Trovik J, Kalland KH, Salvesen HB, Krakstad C. Androgen receptor as potential therapeutic target in metastatic endometrial cancer (2016). Oncotarget 7:49289-49298.
Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses (201. Oncotarget 6:39676-91.
Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, Stefansson I, Trovik J, Kalland KH, Chen HW, Salvesen HB.
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma (2015). Oncotarget 6: 28440-52.
Stefansson IM, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G, Haldorsen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget 6:10634-45, 2015.
Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 6:1327-39, 2015.
Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol Oncol. 2014 Sep;134(3):599-606, 2014.
Engerud H, Tangen IL, Berg A, Kusonmano K, Halle MK, Oyan AM, Kalland KH, Stefansson I, Trovik J, Salvesen HB, Krakstad C. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. Br J Cancer. May 22. doi: 10.1038/bjc.2014.262, 2014.
Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB. Switch in FOXA1 Status Associates with Endometrial Cancer Progression. PLoS One. 2014 May 21;9(5):e98069, 2014.
Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget 5:1052-61, 2014.
Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Mol Cancer Res.12:754-64, 2014.
Engerud H, Tangen IL, Berg A, Kusonmano K, Halle MK, Oyan AM, Kalland KH, Stefansson I, Trovik J, Salvesen HB, Krakstad C. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. Br J Cancer. May 22. doi: 10.1038/bjc.2014.262, 2014.
Tangen IL, Krakstad C, Halle MK, Werner HM, Oyan AM, Kusonmano K, Petersen K, Kalland KH, Akslen LA, Trovik J, Hurtado A, Salvesen HB. Switch in FOXA1 Status Associates with Endometrial Cancer Progression. PLoS One. 2014 May 21;9(5):e98069, 2014.
Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Mol Cancer Res.12:754-64, 2014.
Qu, Y., A. M. Oyan, R. H. Liu, Y. P. Hua, W. D. Zhang, J. G. Zhang, R. Hovland, M. Popa, X. J. Liu, K. A. Brokstad, R. Simon, A. Molven, B. Lin, W. D. Zhang, E. McCormack, K. H. Kalland and X. S. Ke. 2013. Generation of Prostate Tumor-initiating Cells is Associated with Elevation of Reactive Oxygen Species and IL6/STAT3 Signaling. Cancer Research 73:7090-100, 2013.
Olsen, JR, Oyan AM, Rostad K., Hellem M., Lu L., Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B., and Kalland KH. 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLoS ONE 8(5):e62547, 2013.
Qu, Y., W. C. Li, M. R. Hellem, K. Rostad, M. Popa, E. McCormack, A. M. Oyan, K. H. Kalland, and X. S. Ke. 2013. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer 133:544-55, 2013.
Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB. Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. PLoS One :e54873. doi: 10.1371/journal.pone.0054873, 2013.
Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB. High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. Clin Cancer Res 19:2331-41, 2013.
Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB. Lack of Estrogen Receptor-α Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma. Clin Cancer Res. 19:1094-105, 2013.
Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol. 26:428-34, 2013.
Petersen K, Rajcevic U, Abdul Rahim SA, Jonassen I, Kalland KH, Jimenez CR, Bjerkvig R, Niclou SP. Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model. PLoS ONE 9;8(7):e68288, 2013.
Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A. 109:8699-704, 2012.
Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 12:169, 2012.
Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer. 107:1997-2004, 2012.
Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS ONE. :e52795. doi: 10.1371/journal.pone.0052795, 2012.
Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Oyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB. Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. Br J Cancer. doi: 10.1038/bjc. 2012.
Moen I, Jevne C, Wang J, Kalland KH, Chekenya M, Akslen LA, Sleire L, Enger PØ, Reed RK, Øyan AM, Stuhr LE. Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation. BMC Cancer. 12:21, 2012.